PMID: 15378131Sep 21, 2004Paper

Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials

Journal of Cardiovascular Pharmacology and Therapeutics
Bernard R Chaitman

Abstract

A number of newer antianginal agents, including nicorandil, trimetazidine, and ivabradine, have been synthesized in recent years, but ranolazine, a piperazine derivative that partially inhibits fatty acid oxidation and the late INa current in animal models, is of particular interest mechanistically. Earlier clinical trials with immediate-release ranolazine led to the current sustained-release version tested in the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) (n = 193) and Combination Assessment of Ranolazine In Stable Angina (CARISA) trials (n = 823) of patients with chronic angina and severe limitation of exercise capacity (ie, < 5 metabolic equivalents). MARISA was a placebo-controlled, randomized trial that compared ranolazine monotherapy (500 mg, 1000 mg, and 1500 mg, twice daily) to placebo. CARISA was a placebo-controlled trial that randomized patients on background beta-blocker or calcium antagonist therapy to placebo or ranolazine (750 mg or 1000 mg, twice daily). Both studies showed a significant increase in total exercise duration, time to angina onset, and time to 1 mm ST segment depression. The average magnitude of increase in exercise duration over placebo was 29 to 56 seconds at peak and 24 to 46...Continue Reading

References

Jun 1, 1987·Annals of Internal Medicine·D B MarkD B Pryor
Nov 1, 1985·Journal of the American College of Cardiology·D D WatersP A Crean
Sep 1, 1981·Clinical Pharmacology and Therapeutics·B F McGrawJ S Schroeder
Dec 1, 1994·Journal of Cardiovascular Pharmacology·S C BlackB R Lucchesi
Apr 1, 1994·Cardiovascular Drugs and Therapy·U ThadaniS Hobbs
Aug 1, 1994·Cardiovascular Research·M R GralinskiB R Lucchesi
Jan 1, 1995·Rapid Communications in Mass Spectrometry : RCM·A D PenmanY Liu
Apr 1, 1996·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A Y ChenG E Thibault
Apr 29, 1998·General Pharmacology·J G McCormackA A Wolff
Nov 20, 1998·Journal of the American College of Cardiology·K P AlexanderE D Peterson
Jun 1, 1999·JAMA : the Journal of the American Medical Association·P A HeidenreichM A Hlatky
Apr 12, 2001·The New England Journal of Medicine·P W SerruysUNKNOWN Arterial Revascularization Therapies Study Group
Mar 19, 2002·Journal of the American College of Cardiology·Michael C KimSamin K Sharma
Mar 20, 2002·Circulation·Cindy L GrinesRobert L Engler
May 4, 2002·Heart Failure Reviews·Nandakumar SambandamMichael F Allard
May 4, 2002·Heart Failure Reviews·Andrew A WolffRoberto Ferrari
May 9, 2002·Expert Opinion on Investigational Drugs·William C Stanley
Jul 3, 2002·Circulation·David R Holmes, Bernard J Gersh
Aug 24, 2002·Circulation Research·Margaret P ChandlerHani N Sabbah
Mar 28, 2003·American Heart Journal·John S RumsfeldJohn A Spertus
Apr 16, 2003·The Medical Clinics of North America·R FerrariG Guardigli
Nov 5, 2003·Circulation·Viola VaccarinoHarlan M Krumholz
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·R S Schofield, J A Hill
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Charles AntzelevitchGuillermo Perez
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh, Nitin Wadhani

❮ Previous
Next ❯

Citations

Mar 1, 2012·Seminars in Cardiothoracic and Vascular Anesthesia·Anja FrankTobias Eckle
Jul 1, 2005·Future Cardiology·Luigi Tavazzi
Mar 4, 2014·Indian Heart Journal·Aditi VaishnavYash Lokhandwala
Jun 27, 2013·The Journal of Physiology·Zhuo FuZhenqi Liu
Mar 21, 2012·The Canadian Journal of Cardiology·John D Parker, John O Parker
May 31, 2016·Journal of Cachexia, Sarcopenia and Muscle·Elisabetta FerraroGiuseppe Rosano
Dec 12, 2007·British Journal of Pharmacology·D A Saint
Nov 29, 2007·Pharmacotherapy·Paul P Dobesh, Toby C Trujillo
Dec 4, 2012·International Journal of Cardiology·Cristiana VitaleGiuseppe M C Rosano
Jun 1, 2014·Journal of Molecular and Cellular Cardiology·Chunyun DuJules C Hancox
Feb 28, 2014·Clinical Medicine Insights. Therapeutics·Mohammed AldakkakAmadou K S Camara
Nov 28, 2013·Journal of the American Heart Association·Marina BayevaHossein Ardehali
May 2, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lorenza SperanzaGraziano Riccioni
Dec 13, 2005·Coronary Artery Disease·William C Stanley
Sep 27, 2005·Expert Review of Cardiovascular Therapy·William C Stanley
Jan 21, 2010·Physiological Reviews·Gary D LopaschukWilliam C Stanley
Jun 3, 2011·Journal of Cardiovascular Pharmacology·Gong ZhaoLuiz Belardinelli
Nov 10, 2013·Postgraduate Medicine·Robert A KlonerScarlett Geunes-Boyer
Nov 23, 2006·Molecular and Cellular Biochemistry·Sajal ChakrabortiTapati Chakraborti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.